222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
Showing 1 to 10 of 33 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05667922 (ClinicalTrials.gov) | June 2023 | 7/12/2022 | Prognostic Model of TAC in the Treatment of MN | Development and Validation of a Prognostic Model for Idiopathic Membranous Nephropathy Treated With Tacrolimus Development and Validation of a Prognostic Model for Idiopathic Membranous Nephropathy Treated With ... | Idiopathic Membranous Nephropathy | Drug: Tacrolimus | Qianfoshan Hospital | NULL | Not yet recruiting | 18 Years | 75 Years | All | 50 | NULL | |
| 2 | NCT05667896 (ClinicalTrials.gov) | June 2023 | 7/12/2022 | Prognostic Model of GC/TAC in the Treatment of MN | Development and Validation of a Prognostic Model for Idiopathic Membranous Nephropathy Treated With Glucocorticoids Plus Tacrolimus Development and Validation of a Prognostic Model for Idiopathic Membranous Nephropathy Treated With ... | Idiopathic Membranous Nephropathy | Drug: glucocorticoid + tacrolimus | Qianfoshan Hospital | NULL | Not yet recruiting | 18 Years | 75 Years | All | 50 | NULL | |
| 3 | NCT05707377 (ClinicalTrials.gov) | April 2023 | 23/1/2023 | A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous ... | A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy a ... | Primary Membranous Nephropathy | Drug: Zanubrutinib;Drug: Tacrolimus | BeiGene | NULL | Not yet recruiting | 18 Years | 75 Years | All | 282 | Phase 2/Phase 3 | NULL |
| 4 | NCT05532111 (ClinicalTrials.gov) | September 1, 2022 | 1/9/2022 | Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial | Efficacy and Safety of Rituximab Combined With Tacrolimus in the Treatment of Intermediate-to-high Risk Primary Membranous Nephropathy: A Randomized Clinical Trial Efficacy and Safety of Rituximab Combined With Tacrolimusin the Treatment of Intermediate-to-high Ri ... | Efficacy and Safety | Drug: Rituximab combined with tacrolimus induction + rituximab maintenance;Drug: Rituximab combined with tacrolimus induction + tacrolimus maintenance;Drug: Glucocorticoid combined with cyclophosphamide induction + maintenance Drug: Rituximabcombined with tacrolimusinduction + rituximab maintenance;Drug: Rituximabcombined wit ... | RenJi Hospital | NULL | Not yet recruiting | 18 Years | 75 Years | All | 60 | N/A | NULL |
| 5 | ChiCTR2200056304 | 2022-04-29 | 2022-02-03 | Efficacy and safety of Tripterygium Hypoglaucum Root Tablet combined with Tacrolimus Therapy in primary membranous nephropathy with moderate risk: A double-blind, randomised, controlled trial Efficacy and safety of Tripterygium Hypoglaucum Root Tablet combined with TacrolimusTherapy in prima ... | Efficacy and safety of Tripterygium Hypoglaucum Root Tablet combined with Tacrolimus Therapy in primary membranous nephropathy with moderate risk: A double-blind, randomised, controlled trial Efficacy and safety of Tripterygium Hypoglaucum Root Tablet combined with TacrolimusTherapy in prima ... | primary membranous nephropathy with moderate risk | control group:tacrolimus combined with placebo;Experimental group:tacrolimus combined with Colquhounia Root Tablets; control group:tacrolimuscombined with placebo;Experimental group:tacrolimuscombined with Colquhounia ... | The First Affiliated Hospital, College of Medicine, Zhejiang University | NULL | Pending | 45 | 75 | Both | control group:60;Experimental group:60; | Phase 4 | China |
| 6 | ChiCTR2200058661 | 2022-04-01 | 2022-04-13 | Clinical assessment of tacrolimus in treating patients with membranous nephropathy: A protocol for systematic review and meta-analysis Clinical assessment of tacrolimusin treating patients with membranous nephropathy: A protocol for sy ... | Clinical assessment of tacrolimus in treating patients with membranous nephropathy: A protocol for systematic review and meta-analysis Clinical assessment of tacrolimusin treating patients with membranous nephropathy: A protocol for sy ... | Membranous nephropathy | Experimental group:Tacrolimus;Control group:Other treatment; | People’s Hospital of Songzi | NULL | Pending | 18 | 70 | Both | Experimental group:30;Control group:30; | N/A | China |
| 7 | ChiCTR2100048518 | 2021-10-31 | 2021-07-09 | A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequential regimen and low-dose multi-target regimen in the treatment of idiopathic membranous nephropathy A prospective, multi-center, real-world clinical trial of tacrolimuscombined with belimumab sequenti ... | A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequential regimen and low-dose multi-target regimen in the treatment of idiopathic membranous nephropathy A prospective, multi-center, real-world clinical trial of tacrolimuscombined with belimumab sequenti ... | idiopathic membranous nephropathy | low-dose multi-target group:No;tacrolimus combined with belimumab sequential group:No;intravenous cyclophosphamide pulse group:No; low-dose multi-target group:No;tacrolimuscombined with belimumabsequential group:No;intravenous cycl ... | The Second Affiliated Hospital of Xi'an Jiaotong University | NULL | Pending | 18 | 70 | Both | low-dose multi-target group:100;tacrolimus combined with belimumab sequential group:100;intravenous cyclophosphamide pulse group:100; | China | |
| 8 | NCT04629248 (ClinicalTrials.gov) | June 25, 2021 | 27/10/2020 | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous N ... | A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Effica ... | Primary Membranous Nephropathy | Drug: Obinutuzumab;Drug: Tacrolimus;Drug: Methylprednisolone;Drug: Acetaminophen;Drug: Diphenhydramine Drug: Obinutuzumab;Drug: Tacrolimus;Drug: Methylprednisolone;Drug: Acetaminophen;Drug: Diphenhydrami ... | Hoffmann-La Roche | NULL | Recruiting | 18 Years | 75 Years | All | 140 | Phase 3 | United States;Argentina;Brazil;China;France;Israel;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;Peru United States;Argentina;Brazil;China;France;Israel;Italy;Poland;Russian Federation;Spain;Turkey;Ukra ... |
| 9 | EUCTR2020-003233-38-PL (EUCTR) | 13/04/2021 | 24/02/2021 | A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropa ... | A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFIC ... | Primary Membranous Nephropathy (pMN) MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Primary Membranous Nephropathy (pMN) MedDRA version: 21.1;Level: LLT;Classification code 10027170;Te ... | Trade Name: Gazyvaro Product Name: Obinutuzumab Product Code: RO5072759 INN or Proposed INN: OBINUTUZUMAB Other descriptive name: OBINUTUZUMAB/ GA101 Product Name: Tacrolimus Product Code: RO0485337 INN or Proposed INN: Tacrolimus Product Name: Tacrolimus Product Code: RO0485337 INN or Proposed INN: Tacrolimus Trade Name: Gazyvaro Product Name: Obinutuzumab Product Code: RO5072759 INN or Proposed INN: OBINUTUZUM ... | F.Hoffmann-La Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Phase 3 | United States;Spain;Ukraine;Turkey;Israel;Russian Federation;Italy;France;Canada;Argentina;Poland;Brazil;Peru;China United States;Spain;Ukraine;Turkey;Israel;Russian Federation;Italy;France;Canada;Argentina;Poland;Br ... | ||
| 10 | EUCTR2020-003233-38-IT (EUCTR) | 06/04/2021 | 04/06/2021 | A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropa ... | A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY - A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropa A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFIC ... | Primary Membranous Nephropathy (pMN) MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Primary Membranous Nephropathy (pMN) MedDRA version: 21.1;Level: LLT;Classification code 10027170;Te ... | Trade Name: Gazyvaro Product Name: Obinutuzumab Product Code: [RO5072759] INN or Proposed INN: OBINUTUZUMAB Other descriptive name: OBINUTUZUMAB/ GA101 Trade Name: Prograf Product Name: Tacrolimus Product Code: [RO0485337] INN or Proposed INN: TACROLIMUS Trade Name: Prograf Product Name: Tacrolimus Product Code: [RO0485337] INN or Proposed INN: TACROLIMUS Trade Name: Adoport Product Name: Tacrolimus Product Code: [RO0485337] INN or Proposed INN: TACROLIMUS Trade Name: Prograf Product Name: Tacrolimus Product Code: [RO0485337] INN or Proposed INN: TACROLIMUS Trade Name: Adoport Product Name: Tacrolimus Product Code: [RO0485337] INN or Proposed INN: TACROLIMUS Trade Name: Gazyvaro Product Name: Obinutuzumab Product Code: [RO5072759] INN or Proposed INN: OBINUTUZ ... | F. HOFFMANN - LA ROCHE LTD. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Phase 3 | United States;Spain;Ukraine;Turkey;Israel;Russian Federation;Italy;France;Canada;Argentina;Brazil;Poland;Peru;China United States;Spain;Ukraine;Turkey;Israel;Russian Federation;Italy;France;Canada;Argentina;Brazil;Po ... |